PubMed Health⌕ Search

PubMed · 10502976

[Changes in the approach to epilepsy].

Abstract

The last decades resulted unlikely development in the investigation and therapy of epilepsy. This process made the classification and separation of the epileptic seizures and epileptic syndromes possible. The new classification established the functional assessment of the convulsive disorder and revealed the fact that epilepsy is not only a symptom but an illness. The new computer assisted neuroimaging methods disclose more and more details in the etiology and extremely reduce the number of cryptogen epilepsies. Understanding the role of different ionchanels and certain excitatory and inhibitory transmitters in the generation and propagation of epileptic excitement gives new possibilities in therapeutic approach. The pharmacokinetic features of the antiepileptic drugs basically determined therapeutic concepts. Most of the antiepileptic drugs exert their therapeutical effect through their blood level. This recognition led to the development of the mono and rational polytherapy. In the last five year developed large cohort of the newest antiepileptic drugs and the renaissance of the epilepsy surgery make a revolution in the treatment of the epileptic disorder.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Balogh. 1999-08-29. [Changes in the approach to epilepsy].. https://pubmed.ncbi.nlm.nih.gov/10502976/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗